Literature DB >> 25442041

[(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.

Olgun Elicin1, Sharon Callaway2, John O Prior3, Jean Bourhis1, Mahmut Ozsahin4, Fernanda G Herrera5.   

Abstract

PURPOSE: To quantify the relationship between bone marrow (BM) response to radiation and radiation dose by using (18)F-labeled fluorodeoxyglucose positron emission tomography [(18)F]FDG-PET standard uptake values (SUV) and to correlate these findings with hematological toxicity (HT) in cervical cancer (CC) patients treated with chemoradiation therapy (CRT). METHODS AND MATERIALS: Seventeen women with a diagnosis of CC were treated with standard doses of CRT. All patients underwent pre- and post-therapy [(18)F]FDG-PET/computed tomography (CT). Hemograms were obtained before and during treatment and 3 months after treatment and at last follow-up. Pelvic bone was autosegmented as total bone marrow (BMTOT). Active bone marrow (BMACT) was contoured based on SUV greater than the mean SUV of BMTOT. The volumes (V) of each region receiving 10, 20, 30, and 40 Gy (V10, V20, V30, and V40, respectively) were calculated. Metabolic volume histograms and voxel SUV map response graphs were created. Relative changes in SUV before and after therapy were calculated by separating SUV voxels into radiation therapy dose ranges of 5 Gy. The relationships among SUV decrease, radiation dose, and HT were investigated using multiple regression models.
RESULTS: Mean relative pre-post-therapy SUV reductions in BMTOT and BMACT were 27% and 38%, respectively. BMACT volume was significantly reduced after treatment (from 651.5 to 231.6 cm(3), respectively; P<.0001). BMACT V30 was significantly correlated with a reduction in BMACT SUV (R(2), 0.14; P<.001). The reduction in BMACT SUV significantly correlated with reduction in white blood cells (WBCs) at 3 months post-treatment (R(2), 0.27; P=.04) and at last follow-up (R(2), 0.25; P=.04). Different dosimetric parameters of BMTOT and BMACT correlated with long-term hematological outcome.
CONCLUSIONS: The volumes of BMTOT and BMACT that are exposed to even relatively low doses of radiation are associated with a decrease in WBC counts following CRT. The loss in proliferative BM SUV uptake translates into low WBC nadirs after treatment. These results suggest the potential of intensity modulated radiation therapy to spare BMTOT to reduce long-term hematological toxicity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25442041     DOI: 10.1016/j.ijrobp.2014.08.017

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial.

Authors:  Tahir Yusufaly; Austin Miller; Ana Medina-Palomo; Casey W Williamson; Hannah Nguyen; Jessica Lowenstein; Charles A Leath; Ying Xiao; Kevin L Moore; Katherine M Moxley; Carlos M Chevere-Mourino; Tony Y Eng; Tarrick Zaid; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-03       Impact factor: 7.038

2.  The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation.

Authors:  Y M Zhou; C Freese; T Meier; D Go; K Khullar; M Sudhoff; M Lamba; J Kharofa
Journal:  Clin Transl Oncol       Date:  2017-10-26       Impact factor: 3.405

3.  [(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients.

Authors:  Jeffrey C Wyss; Ruben Carmona; Roshan A Karunamuni; Jakub Pritz; Carl K Hoh; Loren K Mell
Journal:  Radiother Oncol       Date:  2015-12-07       Impact factor: 6.280

4.  Feasibility of bone marrow sparing volumetric modulated arc therapy to spare active bone marrow in cervical and vaginal cancer patients: a retrospective dosimetric analysis.

Authors:  Michaela Beavan; Kylie Dundas; Felicity Hudson; Yolanda Surjan; Annie Lau; Shrikant Deshpande; Karen Lim; Viet Do
Journal:  J Med Radiat Sci       Date:  2021-07-19

5.  Longitudinal FDG-PET Revealed Regional Functional Heterogeneity of Bone Marrow, Site-Dependent Response to Treatment and Correlation with Hematological Parameters.

Authors:  Masashi Yagi; Jerry Froelich; Luke Arentsen; Ryan Shanley; Rahel Ghebre; Douglas Yee; Susanta Hui
Journal:  J Cancer       Date:  2015-04-15       Impact factor: 4.207

6.  Imaging Radiation-Induced Gastrointestinal, Bone Marrow Injury and Recovery Kinetics Using 18F-FDG PET.

Authors:  Tien T Tang; David A Rendon; Janice A Zawaski; Solmaz F Afshar; Caterina K Kaffes; Omaima M Sabek; M Waleed Gaber
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

7.  Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.

Authors:  Pierfrancesco Franco; Christian Fiandra; Francesca Arcadipane; Elisabetta Trino; Francesca Romana Giglioli; Riccardo Ragona; Umberto Ricardi
Journal:  BMC Cancer       Date:  2017-11-02       Impact factor: 4.430

Review 8.  Analysis of mRNA Expression Patterns in Peripheral Blood Cells of 3 Patients With Cancer After the First Fraction of 2 Gy Irradiation: An Integrated Case Report and Systematic Review.

Authors:  Yue-Hua Nie; Xiao-Dan Liu; Ruixue Huang; Da-Fei Xie; Wen-Jun Yin; Hua Guan; Zi-Jian Yu; Ping-Kun Zhou
Journal:  Dose Response       Date:  2019-02-26       Impact factor: 2.658

Review 9.  The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity.

Authors:  Hossein Jadvar
Journal:  Diagnostics (Basel)       Date:  2017-07-20

10.  Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy.

Authors:  Lucas K Vitzthum; Elena S Heide; Helen Park; Casey W Williamson; Paige Sheridan; Minh-Phuong Huynh-Le; Igor Sirak; Lichun Wei; Rafal Tarnawski; Umesh Mahantshetty; Cammie Nguyen; Jyoti Mayadev; Catheryn M Yashar; Assuntina G Sacco; Loren K Mell
Journal:  Front Oncol       Date:  2020-07-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.